On May 28, 2025, Viva Biotech Holdings (“the Company”, stock code: 1873.HK) announced that Hangzhou Viva Zongchen, a wholly-owned subsidiary of the Company, Nanjing Ruihong, Nanjing High-Quality, Nanjing BPV, Nanjing Yangzi, Nanjing Beilian, Nanjing New Town, Nanjing Gaoxin, Shanghai Hongene, BrightGene Bio-Medical, and Jiangsu Dingtai entered into the Joint Venture Agreement, pursuant to which the parties agreed to establish the Fund, pursuant to which Hangzhou Viva Zongchen will participate in the newly formed Fund as a limited partner. Pursuant to the Joint Venture Agreement. The total fund size is RMB 300 million, of which Hangzhou Viva Zongchen contributed RMB 25 million, accounting for 8.3%.
The fund is jointly established with Nanjing Ruihong serving as the general partner and Hangzhou Viva Zongchen, along with other institutions, acting as limited partners. The fund has a duration of seven years, with the first three years designated as the investment period and the following four years as the exit period. All parties will work together in a market-oriented and professional manner to promote capital integration and the transformation of achievements in the biopharmaceutical sector.
Sustained Focus on Biopharmaceutical Innovation to Build a Collaborative Industrial Ecosystem
The fund will focus on early-stage pharmaceutical discovery and development projects, with particular attention to cutting-edge technological innovations and their translation in the life sciences sector. It aims to discover and incubate innovative pharmaceutical companies with core technological advantages and strong market potential. The establishment of the fund not only provides critical financial support to early-stage projects but also creates a more efficient bridge between local industrial clusters and innovative enterprises, promoting the formation of a healthy and sustainable industrial ecosystem.
As a world-leading one-stop CRO and CDMO service platform, Viva Biotech is dedicated to delivering high-quality drug discovery and manufacturing services to global clients, while identifying and investing in high-potential biopharmaceutical startups. Through its proprietary Equity-for-Service (EFS) incubation model, the Company is committed to addressing unmet clinical needs and building an open and collaborative platform to empower global biotech innovation. Viva Biotech's participation in the establishment of this Fund will further enhance its awareness of cutting-edge technology developments and emerging industry trends, expand its strategic footprint, and support the exploration of alternative incubation models that complement the EFS approach. This will also create broader opportunities for deepening cooperation with potential strategic partners.
Dr. Cheney Mao, Chairman and CEO of Viva Biotech, stated, “We are pleased to collaborate with our partners in advancing the early-stage innovation ecosystem in drug discovery. Our participation in launching this Fund represents a strategic step forward for Viva Biotech. It will help us explore more models to the EFS investment incubation framework, broaden collaboration channels for early-stage projects, and strengthen our integrated platform capabilities. We remain committed to expanding our industry network and injecting new momentum into the development of innovative therapeutics.”
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us